Abstract:Введение. Потребность в лечении офтальмологических осложнений сахарного диабета остается высокой ввиду неуклонного роста числа пациентов с данной патологией. Формы диабетического макулярного отека (ДМО), ассоциированные с наличием аномалий витреомакулярного интерфейса (АВМИ), требуют дифференцированного подхода к тактике ведения пациентов и технике выполнения витреоретинальных хирургических операций. Цель. Демонстрация возможностей метода дозированного центрсберегающего пилинга внутренней пограничной мембраны сетчатки (ДЦСП ВПМ) в лечении ДМО. Материалы и методы. Представлены два клинических наблюдения – случаи лечения ДМО с АВМИ с применением метода ДЦСП ВПМ. В обоих случаях пациентам проведено комбинированное лечение – факоэмульсификация катаракты с имплантацией интраокулярной линзы в сочетании с витрэктомией с мембранопилингом по методике ДЦСП ВПМ. Период послеоперационного наблюдения составил 12 месяцев. Результаты. В ходе динамического наблюдения в первые 3–6 месяцев после лечения отмечали положительную анатомо-функциональную динамику. К 6-му месяцу в обоих случаях выявлено развитие ДМО, что потребовало применения anti-VEGF-терапии. В случае 1 к 12-му месяцу наблюдения отмечали анатомическое улучшение, но за счет формирования твердого экссудата в области fovea centralis острота зрения оказалась ниже исходной. В случае 2 на фоне лечения отмечали медленную положительную динамику течения ДМО с сохранением зрительной функции на уровне послеоперационной. В обоих случаях не наблюдали интра- и послеоперационных осложнений пилинга ВПМ, таких как формирование ятрогенных разрывов сетчатки, отслойки нейроэпителия, развитие послеоперационного эпимакулярного фиброза. Заключение. ДЦСП ВПМ является примером метода протекции fovea centralis в ходе хирургического лечения. Указанные технологии являются перспективными, однако требуют изучения на репрезентативном клиническом материале. Introduction. The need for the treatment of diabetes mellitus (DM) ophthalmic complications remains high due to the steady increase in the number of patients. Forms of diabetic macular edema (DME) associated with the presence of the vitreomacular interface anomalies (VMIA) require a differentiated approach to the management and vitreoretinal surgery technique. Purpose. To demonstrate the possibilities of method of the dosed fovea-sparing peeling of the retinal internal limiting membrane (DFSP ILM) in the DME treatment. Materials and methods. Two clinical observations are presented – cases of VMIA-DME treatment using the DFSP ILM method. In both cases, the patients underwent combined treatment: cataract phacoemulsification with intraocular lens implantation in combination with vitrectomy (VRS) with DFSP ILM peeling. The postoperative follow-up period was 12 months. Results. During the dynamic observation in the first 3–6 months after treatment, positive anatomical and functional results were noted. By the 6th month, the development of DME was detected in both cases, which required the use of anti-VEGF therapy. In case 1, by the 12th month of observation, anatomical improvement was noted, but due to the formation of hard exudate in the fovea centralis area, visual acuity was lower than the initial one. In case 2, against the background of treatment, a slow positive dynamics of DME was noted with the preservation of visual function at the postoperative level. In both cases, intra- and postoperative complications of DFSP ILM peeling were not observed, such as the formation of iatrogenic retinal tears, detachment of the neuroepithelium, and the development of postoperative epimacular membrane. Conclusion. DFSP ILM is an example of a fovea centralis protection method during VRS. These technologies are promising, however, they require study on representative clinical material.

Investigation of regional hemodynamics and structural and functional changes in the macular region in patients with intermediate stage of dry AMD against the background of the use of double filtration plasmapheresis

Retinal arteriolar calibre and venular fractal dimension predict progression of proliferative diabetic retinopathy 6 months after panretinal photocoagulation: a prospective, clinical interventional study

Retinal oxygen saturation, vessel diameter and flicker response in eyes with specific subtypes of neovascular age-related macular degeneration during aflibercept treatment.

An Analysis of Optical Coherence Tomography Angiography (OCT-A) Perfusion Density Maps in Patients Treated for Retinal Vein Occlusion with Intravitreal Aflibercept

Changes in Ocular Blood Flow After Intravitreal Injection for Diabetic Macular Edema Between Aflibercept and Faricimab

Dosed Fovea-Sparing Internal Limiting Membrane Peeling in Diabetic Macular Edema Treatment (Clinical Observations)

Experience in using the capabilities of laser speckle flowgraphy in macular edema associated with retinal vein occlusions (preliminary report)

Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 1

Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy

A Preliminary Study of Double Filtration Plasmapheresis in ANCA Associated Vasculitis with Severe Renal Involvement

Effect of Intravitreal Aflibercept on Wet Age-Related Macular Degeneration and Evaluation of Risk Factors on Patient’s Response

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion

Pro re nata Treatment of Diabetic Macular Edema with Cycles of Three Injections of Anti-vascular Endothelial Growth Factor Injections

Combined treatment modalities in wet AMD

Long-term results (60 months) of anti-VEGF therapy of macular diseases in real clinical practice. Part 2.

Short-term effects of anti-VEGF drugs on macular perfusion in patients with diabetic macular edema

Macular vessel density before and after panretinal photocoagulation in patients with proliferative diabetic retinopathy

Effects of switching from intravitreal injection of aflibercept to faricimab on ocular blood flow in patients with diabetic macular edema

Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept

Influence of different fluid types on the development of fibrosis and atrophy in patients with nAMD

Efficacy and safety of efdamrofusp alfa versus aflibercept in participants with neovascular age-related macular degeneration: a randomized, double-masked, active-controlled, non-inferiority, phase 2 trial